Medical Developments grows Penthrox market share in UK and Ireland
Published 08-FEB-2017 14:57 P.M.
|
2 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Shares in Medical Developments (ASX: MVP) initially surged more than 5% in afternoon trading after the group announced promising uptake of its Penthrox product (often referred to as the green whistle) in the United Kingdom.
However, the company’s share price quickly retraced, perhaps indicating that investors are mainly focused on entry into mainland Europe where the group has 22 applications submitted to the United Kingdom’s Medicine and Healthcare Products Regulatory Agency (MHRA) under the decentralised procedure in November 2016.
Medical Developments share price ran strongly in the early part of 2016 more than doubling from less than $3.00 to hit an all-time high of $6.85, but in the second half they retraced to strike a six month low of $4.12 in December. In the last month they have recovered slightly to trade in a tight range between $5.00 and $5.50.
It should be noted that share trading patterns should not be used as the basis for an investment as they may not be replicated. Those considering this stock should seek independent financial advice.
From an operational perspective, Chief Executive, Jon Sharman said, “MVP expects approvals will be received to sell Penthrox in these 22 countries and another 15 countries via the National Approval process during the course of 2017 and 2018”.
The company’s success in the UK has been built around use of the fast onset, non-opioid analgesic in hospitals and trauma centres, effectively replicating its applications in Australia where it has been used safely and effectively for more than 30 years with more than 5 million units sold.
Galen, the entity appointed by MVP to supply Penthrox in the United Kingdom and Ireland has made good progress, and 34 hospitals have approved and are now using Penthrox.
There are 11 major trauma centre hospitals in the UK, four of which have approved and are using Penthrox.
Medical Developments expects further uptake of the product in this area with Sharman saying, “Recent success in the major trauma centres in the UK and Ireland is very encouraging and the feedback from the market is very positive, leading us to expect a number of additional hospital and ambulance trusts will approve Penthrox in the coming months”.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.